June 24, 2021 —Johnson & Johnson Innovation announced today that Biorchestra has been selected as the awardee in the NYC Innovation QuickFire Challenge on Neuroscience. The challenge invited innovators in neuroscience to submit ideas aimed at reducing the burden and disability caused by serious neuropsychiatric, neurological and neurodegenerative diseases.
To help advance their research, Biorchestra will receive a total of $25,000 in grant funding, one year of residency at JLABS @ NYC - with the use of a bench, workstation and access to the JLABS @ NYC community, and mentorship from experts from the Johnson & Johnson Family of Companies*.
Biorchestra is a Biomarker-driven RNA therapeutics company focusing on neurodegenerative diseases and rare genetic diseases. The company's platform has developed therapeutic candidates for Alzheimer's disease, mRNA vaccine, and drug delivery systems for RNA candidates, with the aim to help doctors improve the health of humankind.
The QuickFire Challenges are managed by Johnson & Johnson Innovation—JLABS, with the goal to help address today’s greatest health care challenges.
* subject to the execution of the necessary agreements
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.
About JLABS @ NYC
JLABS @ NYC — a 30,000-square foot facility located at the New York Genome Center —supports the next generation of innovation leaders by enabling and encouraging early-stage companies aiming to transform the science of today into the breakthrough healthcare potential solutions of tomorrow.
By applying the unique Johnson & Johnson Innovation - JLABS model to New York’s dynamic, entrepreneurial spirit, JLABS @ NYC aims to convene the brightest talent from around the region with industry experts to push the boundaries of science and collaborate across a shared community.
Since its launch in 2018, JLABS @ NYC has welcomed 49 resident companies to its family across the pharmaceutical, medical device, health tech, and consumer sectors. With the continuous need to help advance science with the aim to conquer our world’s evolving health challenges, JLABS @ NYC is actively searching for the brightest minds with transformative ideas on how to improve health and wellness – and we believe that the next big breakthroughs in healthcare could begin within academia and this rising generation of innovators.